# Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

> **NCT06934590** · PHASE1 · NOT_YET_RECRUITING · sponsor: **GeneCraft Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** RX001

## Key facts

- **NCT ID:** NCT06934590
- **Lead sponsor:** GeneCraft Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06934590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06934590, "Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06934590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*